Search: onr:"swepub:oai:DiVA.org:uu-139190" >
Treatment of malign...
Treatment of malignant melanoma patients with expanded tumor-infiltrating T cells and low dose IL-2
-
- Sadeghi, Arian, 1977- (author)
- Uppsala universitet,Enheten för klinisk immunologi
-
Ullenhag, Gustav (author)
-
Carlsson, Björn (author)
-
show more...
-
Håkan, Ahlström (author)
-
Mosavi, Firas (author)
-
Wagenius, Gunnar (author)
-
Tötterman, Thomas (author)
-
show less...
-
(creator_code:org_t)
- English.
- Related links:
-
https://urn.kb.se/re...
Abstract
Subject headings
Close
- ABSTRACT Purpose: The prognosis for patients with metastasized malignant melanoma is very poor, and an effective therapy is warranted. Previous studies of adoptive T cell transfer have been encouraging, but have sometimes exhibited severe side effects. We sought to refine earlier applied protocols by using low-dose instead of high-dose IL-2 as a supporting cytokine. Experimental design: We evaluated the adoptive transfer of autologous T cells in combination with low-dose s.c. IL-2 in 28 melanoma patients with advanced disease. The patients had progressed on standard treatments. They were pretreated with high-dose chemotherapy for obtaining lymphodepletion to augment the anti-tumor function of the transferred T cells. Results: The objective response rate was18 %. One patient obtained a long-lasting complete remission and four patients a partial response. Tumor regression was demonstrated in six further patients (21 %) without reaching the RECIST criteria for a partial response. Conclusions: This is the first study in cancer patients with autologous T cell transfer combined with low-dose s.c. IL-2. The results are promising but modifications of the protocol are needed to increase the response rate.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- vet (subject category)
- ovr (subject category)
To the university's database